Articles with "honoraria institution" as a keyword



Photo by wistomsin from unsplash

Splenic metabolic activity as biomarker in cervical cancer

Sign Up to like & get
recommendations!
Published in 2019 at "Annals of Oncology"

DOI: 10.1093/annonc/mdz239.062

Abstract: Abstract Background Inflammation has a significant impact on cervical cancer (CC) development and therapy response. We sought to determine if splenic metabolic activity reflects host immune status and could improve prognostic and predictive categorization of… read more here.

Keywords: travel accommodation; honoraria institution; accommodation expenses; institution ... See more keywords
Photo by srosinger3997 from unsplash

First in human, a phase I study of ISU104, a novel ErbB3 monoclonal antibody, in patients with advanced solid tumours

Sign Up to like & get
recommendations!
Published in 2019 at "Annals of Oncology"

DOI: 10.1093/annonc/mdz244.016

Abstract: Abstract Background ErbB3, a heterodimeric partner of EGFR or ErbB2, is activated by heregulin binding in various cancers. ISU104, blocking ErbB3 activation and dimerization, showed anti-tumor effects in various preclinical models as mono- or combination-therapy.… read more here.

Keywords: honoraria institution; part; consultancy; advisory consultancy ... See more keywords
Photo by jareddrice from unsplash

POLAF study: Efficacy and safety of FOLFIRI/aflibercept in a phase II trial in patients with metastatic colorectal cancer: Results of plasmatic prognostic and predictive markers

Sign Up to like & get
recommendations!
Published in 2019 at "Annals of Oncology"

DOI: 10.1093/annonc/mdz246.062

Abstract: Abstract Background Biomarkers associated to antiangiogiogenic agents in metastatic colorectal cancer (mCRC) have not yet been validated Here we present the efficacy and safety results of FOLFIRI and aflibercept in second line therapy for mCRC… read more here.

Keywords: honoraria institution; honoraria self; advisory consultancy;
Photo by trnavskauni from unsplash

Impact of prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer (ROC): Sub-group analysis from a randomized, open-label study comparing trabectedin (T) and PLD versus PLD alone in ROC (ET743-OVC-3006)

Sign Up to like & get
recommendations!
Published in 2019 at "Annals of Oncology"

DOI: 10.1093/annonc/mdz250.038

Abstract: Abstract Background Retreatment with PLD in ROC has raised potential concerns of increased toxicity and diminished response rates. This subgroup analysis examined the safety and efficacy of platinum-sensitive patients (pts) with prior PLD therapy who… read more here.

Keywords: honoraria institution; institution advisory; pld; advisory consultancy ... See more keywords
Photo by aaronburden from unsplash

The ImmunoTOX multidisciplinary board: A descriptive study of collaborative management of immune-related adverse events

Sign Up to like & get
recommendations!
Published in 2019 at "Annals of Oncology"

DOI: 10.1093/annonc/mdz265.003

Abstract: Abstract Background The adverse events generated by immunotherapies are characterized by their wide diversity, unpredictability and reversibility by steroid used, and requires a delicate management. A collaborative organization of immunological toxicology management called ImmunoTOX (iTox)… read more here.

Keywords: management; honoraria institution; study; advisory consultancy ... See more keywords
Photo by jareddrice from unsplash

Accuracy of pathologic evaluation for thymic epithelial tumors in an Italian reference centre

Sign Up to like & get
recommendations!
Published in 2019 at "Annals of Oncology"

DOI: 10.1093/annonc/mdz266.014

Abstract: Abstract Background Thymic Epithelial Tumors (TETs) are rare entities, which can be diagnostic challenges for Pathologists. It has been proven that patients’ referral to a Center with an expert Pathologist is a key factor in… read more here.

Keywords: self honoraria; honoraria institution; institution advisory; institution ... See more keywords
Photo by trnavskauni from unsplash

Patient reported outcomes during immunotherapy: Symptom burden in daily clinical practice

Sign Up to like & get
recommendations!
Published in 2019 at "Annals of Oncology"

DOI: 10.1093/annonc/mdz276.004

Abstract: Abstract Background PD(L)1-inhibitors can cause immune-related adverse events (irAEs.). IrAEs may be under-recognized and their influence on health-related quality of life (HRQL) underestimated. At this point, insight into patient-reported symptom prevalence and intensity is limited.… read more here.

Keywords: honoraria institution; institution advisory; advisory consultancy; patient reported ... See more keywords
Photo by mariusspita from unsplash

Supportive care to control nausea and dizziness in malignant tumours: A systematic review

Sign Up to like & get
recommendations!
Published in 2019 at "Annals of Oncology"

DOI: 10.1093/annonc/mdz434.030

Abstract: Abstract Background Patients with malignant tumours may suffer from nausea as a side-effect of chemo-/radiotherapy. Antiemetic drugs can cause dizziness, which may lead to falls and decrease quality of life. Complementing research on painkiller-associated dizziness… read more here.

Keywords: honoraria institution; advisory boards; institution; institution honoraria ... See more keywords